Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects
Anti-obesity drugs in the amphetamine (AMPH) class act in the brain to reduce appetite and increase locomotion. They are also characterized by adverse cardiovascular effects with origin that, despite absence of any in vivo evidence, is attributed to a direct sympathomimetic action in the heart. Here...
Main Authors: | Mahú, I, Barateiro, A, Rial-Pensado, E, Domingos, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2020
|
Similar Items
-
Leptin resistance and the neuro-adipose connection
by: Barateiro, A, et al.
Published: (2017) -
A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages
by: Pereira, M, et al.
Published: (2017) -
Results of the nerve-sparing radical prostatectomy in obese patients
by: E. A. Sokolov, et al.
Published: (2020-07-01) -
CYTOKINE PROFILE IN VISCERAL OBESITY AND ADVERSE CARDIOVASCULAR PROGNOSIS OF MYOCARDIAL INFARCTION
by: O. V. Gruzdeva, et al.
Published: (2015-06-01) -
Neuro-mesenchymal units control ILC2 and obesity via a brain–adipose circuit
by: Cardoso, F, et al.
Published: (2021)